Online inquiry

IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7910MR)

This product GTTS-WQ7910MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7910MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12416MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NI-0401
GTTS-WQ7606MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ7316MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ2530MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 334
GTTS-WQ13326MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ7340MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ7911MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ5492MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDP 6038
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW